TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · major macro event coming up
MRNA

Moderna Inc

Healthcare · Biotechnology

59.80$ +1.1% vs. previous close Closing price · As of: Aug 10, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Moderna Inc (MRNA). It shows which part of the business is growing — and which one is holding it back.

Revenue by region

Revenue by region — MRNA
Segment 2020 2021 2022 2023 2024 2025
United States $764.0M 95.1% $6.18B 33.4% · +708.5% $5.15B 26.7% · -16.6% $1.90B 27.7% · -63.2% $1.79B 55.2% · -5.8% $1.20B 61.7% · -32.8%
Rest of world $6.0M 0.7% $5.45B 29.5% · +90,700.0% $7.30B 37.9% · +34.0% $3.60B 52.5% · -50.7% $853.0M 26.4% · -76.3% $692.0M 35.6% · -18.9%
Europe $33.0M 4.1% $6.85B 37.1% · +20,645.5% $6.82B 35.4% · -0.5% $1.36B 19.8% · -80.1% $598.0M 18.5% · -55.9% $53.0M 2.7% · -91.1%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by product line

Revenue by product line — MRNA
Segment 2021
Product sales $17.68B 95.4%
Grant revenue $735.0M 4.0%
Collaboration revenue $61.0M 0.3%
Collaboration Revenue by Strategic Collaborator $61.0M 0.3%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 10, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?